|
My Fellow Survivor,
I have taken the liberty of highlighting what I feel are
the most relevant points of this report on the study.
You will also find my comments in blue throughout the document.
I inserted them to assist you in assessing the results of
this study and to put them in perspective with regard to Maximum
Milk Thistle.
Be well,
Ralph Napolitano
Key text is highlighted for your
convenience. Comments by Ralph Napolitano are in dark
blue.
Journal of Clinical Gastroenterology 2003; 37(4):336-33
Silymarin Retards the Progression of
Alcohol-Induced Hepatic Fibrosis in Baboons
Charles S. Lieber, MD, MACP; Maria A. Leo, MD; Qi Cao, MD,
PhD; Chaoling Ren, MD; Leonore M. DeCarli, BA
Goal/Background:
Hepatoprotective effects of silymarin in patients with alcoholic
liver disease are controversial. For strict control, this
was assessed in non-human primates.
As stated elsewhere, the possible
reason for the controversy is from inconsistent results in
other studies which may have been from lack of control over
dose and compliance. The key words with regard to this study
are "strict control".
Study:
Twelve baboons were fed alcohol with or without silymarin
for 3 years with a nutritionally adequate diet.
Results:
Silymarin opposed the
alcohol-induced oxidative stress (assessed by plasma 4-hydroxynonenal)
and the rise in liver lipids and circulating ALT. Alcohol
also increased hepatic collagen type I by 50% over the 3 years
with a significant rise in mRNA for [alpha]1 (I) procollagen,
both prevented by silymarin. There were corresponding
morphologic changes: at 36 months, 2 of 6 animals fed alcohol
had cirrhosis and 2 septal fibrosis, with perivenular fibrosis
in 2, whereas with alcohol + silymarin, there was only 1 cirrhosis
and 1 septal fibrosis, with perivenular fibrosis in 2, and
virtually no lesions in the remaining 2.
These results indicate a broad reaching
beneficial effect of silymarin against the ravages of liver
disease. It also states that the blood tests and biopsies
were reliable predictors for the actual physical state of
the livers after three years. The subjects with the worse
blood test and biopsy results had the most damage.
Conclusions:
Silymarin
retards the development of alcohol-induced hepatic fibrosis
in baboons, consistent with several positive clinical trials.
The negative
outcome observed in other trials possibly reflects poor compliance
resulting in irregular or low silymarin intake.
Thus, in view of the innocuity of silymarin, it might be advisable
in future clinical studies to insure the controlled administration
of sufficient amounts of silymarin.
This conclusion of this study is
definite. Silymarin retards fibrosis.
Key Words: cirrhosis; collagen; oxidative stress
Received for publication January 7, 2003; accepted May 6,
2003.
From the Section of Liver Disease & Nutrition, Bronx
VA Medical Center & Mount Sinai School of Medicine, Bronx,
New York
Supported, in part, by NIH grant AA11115, the Department
of Veterans Affairs, the Kingsbridge Research Foundation and
MADAUS AG, Cologne, Germany.
Reprints: Dr. Charles S. Lieber, VA Medical Center (151-2),
130 West Kingsbridge Road, Bronx, NY 10468 (e-mail: liebercs@aol.com).
Silymarin, extracted from the milk thistle, is a mixture
of the 3 isomeric compounds silibinin, silidianin, and silichristin;
it has been used traditionally against a variety of liver
ailments.1 Silibinin,
the main isomer, was shown to prevent liver fibrosis induced
by CCl4 in rats.2 It was also found to be a radical scavenger3 and, in patients with alcoholic liver disease,
Silibinin is another word for silybin,
the main active ingredient in Maximum
Milk Thistle. Actually, MMT isolates silybin and then
makes it 8 to 10 times more absorbable, bringing that much
more to your liver.
some randomized controlled trials with silymarin showed beneficial
effects such as improved survival.4 However, other controlled studies
did not verify such an effect.5 Since clinical trials in alcoholics
commonly suffer from significant variability in alcohol consumption
and poor compliance with medications, we assessed the effectiveness
of silymarin under controlled experimental conditions. Specifically,
we addressed the question whether silymarin opposes alcohol-induced
liver injury in terms of oxidative stress, abnormal liver
tests, hepatic steatosis and fibrosis in
non-human primates, which are much closer to man than the
rodents used in all previous experimental studies.
Using baboons gave results which
are more relevant to humans.
MATERIALS AND METHODS
Twelve baboons were studied in accordance with the institutional
guidelines for animal research. They were fed for 36 months
nutritionally adequate liquid diets containing alcohol (50%
of calories),6 half of them supplemented with
silymarin kindly donated by MADAUS AG (Cologne, Germany).
The 2 groups were balanced with regard to sex, weight, and
age. One baboon (#2) started 6 months late. Silymarin was
given in the diet at a dose of 0.84 mg per calorie, an
amount recommended by MADAUS AG as equivalent to the usual
therapeutic dose in humans based on pharmacokinetic tests,
MADAUS AG makes Legalon, a prescription-strength
standardize milk thistle from Germany. Maximum
Milk Thistle has been compared to Legalon in a head to
head clinical study and the absorption rate of silybin was
8 to 10 times greater with MMT. See study
C10.
taking into account the higher metabolic rate in baboons
compared with men. Daily alcohol intake was comparable in
both groups: 2.84 1 0.33 and 3.34 1 0.32 g/kg body weight
for the ethanol and the ethanol + silymarin groups, respectively.
The corresponding data in g/animal/d were 49.8 1 4.6 versus
54.1 1 7.8. Intake of silymarin was 39.8 1 5.2 mg/kg body
weight and 645 1 92 mg/animal/d.
Percutaneous liver biopsies were performed every 6 months
with a Menghini needle. For light microscopy, specimens were
coded for blind reading, prepared, and examined for the various
stages of fibrosis as described before.7, 8 The tissue obtained was adequate
for all morphologic and most chemical assessments except for
a few of the collagen and triglyceride measurements because
of variable yield of the percutaneous needle liver biopsies.
Measurements were carried out of plasma AST, ALT and total
bilirubin (Sigma Kits; SIGMA Diagnostics), 4-hydroxynonenal
by GC/MS,9 hepatic total triglycerides,10 collagen type I,11 and [alpha]1 (I) collagen mRNA.12
RESULTS
Plasma 4-hydroxynonenal increased
strikingly with ethanol, and this was significantly prevented
by silymarin at each of the 6 month time points (Fig. 1) during the first 2 years.
The fact that this increase was
"significantly" prevented is very encouraging with
regard to MMT effectiveness in protecting your liver.
There was a lesser increase of 4-hydroxynonenal in the 3rd
year, possibly as a consequence of diminished metabolism secondary
to liver disease.
FIGURE 1.
Effect of alcohol (with or without silymarin) on plasma
4-hydroxynonenal. Alcohol increased 4-hydroxynonenal and this
was opposed by silymarin, confirming its antioxidative properties.
P values: alcohol versus alcohol + silymarin.(

Plasma ALT values (Fig. 2) were significantly lower after silymarin plus alcohol
than with alcohol alone. There were no significant
differences for AST and bilirubin.
ALT levels are often a better indicator
of serious ongoing liver damage than AST. Keeping these low
is a valuable effect of silymarin in this study.
FIGURE 2.
Effect of alcohol (with or without silymarin) on plasma
ALT. There
was an overall significant attenuation by silymarin of the
alcohol-induced rise in ALT. ns = not significant.
Attenuation is a lessening.

The overall histologic assessment
showed lesser steatosis with silymarin, substantiated by triglyceride
measurement which revealed an increase with ethanol and a
significant reduction with silymarin after 1 year
(161.6 1 37.7 versus 63.5 1 16.8 mg/g liver, P
= 0.04) with a similar effect at 18 months (124.6 1 15.6 versus
69.6 1 12.3 mg/g liver, P = 0.02) and at 24 months
(147.01 22.8 versus 77.2 1 10.1 mg/g liver, P = 0.02).
Both of these observations are strong
testimony to the protective effects of milk thistle at the
one year of treatment mark.
Concerning liver fibrosis, alcohol
feeding resulted in an increase of collagen type I and silymarin
prevented this rise (Figs. 3a, b). In addition, mRNA of [alpha] (I) procollagen
was significantly lower after ethanol + silymarin than after
ethanol alone (Figs. 4a, b). The histologic
stages of fibrosis were consistent with these biochemical
data. Indeed, in terms of the lesions
achieved at 36 months, 4 of the 6 animals fed alcohol had
an advanced stage of disease, reaching cirrhosis in 2 and
septal fibrosis in another 2 (Fig. 5a). By contrast, with alcohol and silymarin, there was
only 1 cirrhosis and 1 septal fibrosis (Fig. 5b). In the animals given ethanol + silymarin, 2 out
of 6 were virtually fully protected after 3 years (Fig. 5b), but only 1 of the 6 animals fed alcohol alone had
such an outcome (Fig. 5a). Histologic scores of the fibrosis were also
decreased by silymarin (P = 0.03 by [chi]2 or Fisher
exact test). Representative lesions observed at 36 months
are shown in Figure 6A-F, illustrating the
differences in steatosis and fibrosis between baboons fed
alcohol with or without silymarin.
Inhibiting fibrosis is the key measure
of effectiveness in slowing the progression of serious liver
disease. Whether from alcohol or viral hepatitis, fibrosis
leads to cirrhosis. As liver cells are killed, scar tissue
is formed. This is fibrosis. At a certain point the scar tissue
inhibits the function of the liver, this is cirrhosis. The
more that functions are inhibited, the more advanced and serious
the cirrhosis. The fact that silymarin dramatically inhibited
fibrosis in this study is one of the strongest testaments
to the daily use of Maximum Milk Thistle
that I have yet encountered.
FIGURE 3.
a, b. Effect of alcohol, with
or without silymarin, on hepatic accumulation of collagen
type I. Already after 18 months of alcohol, there was a significant
rise in hepatic collagen type I (3a); this was prevented by
silymarin which also opposed the subsequent increases (3a,
3b). ns = not significant.
This is more proof of a significant
action against fibrosis.

FIGURE 4.
a, b. Effect of alcohol, with
or without silymarin, on hepatic mRNA of [alpha]1(I) procollagen.
At 18 months, concomitant with the increase in collagen type
I (see Figure 3a), there was a corresponding significant rise
in mRNA (a). This was prevented by silymarin. This protective
effect persisted for the remainder of the 3 years (a,
b).
This shows that even after three
years of daily use, milk thistle extract was still protecting
the liver from fibrosis.

FIGURE 5.
Effect of silymarin on alcohol-induced
hepatic fibrosis. Whereas 4 out of 6 baboons fed alcohol for
36 months developed advanced stages of liver fibrosis, namely
septal fibrosis (SF) in 2 and cirrhosis (C) in another 2 (5a),
there was only 1 cirrhosis and 1 septal fibrosis after alcohol
+ silymarin (5b). PV = perivenular fibrosis. N = normal
histology
This shows that the blood test indicators
were correct in predicting levels of damage. The damage was
commensurate with the markers from the blood tests.

FIGURE 6.
Representative hepatic lesions in
baboons fed alcohol (with or without silymarin) for 36 months.
A. Baboon fed alcohol: Perivenular and pericellular fibrosis.
Marked steatosis involving 75% of the hepatocytes. B. Baboon
fed alcohol + silymarin: Perivenular fibrosis and minimal
steatosis. C. Baboon fed alcohol: Septal fibrosis with incomplete
nodular formation and marked steatosis. D. Baboon fed alcohol
with silymarin. Septal fibrosis. E. Baboon fed alcohol: Cirrhotic
liver with classic nodule surrounded by diffuse fibrosis and
steatosis. F. Baboon fed alcohol + silymarin: Cirrhotic liver
with sparse fibrosis and steatosis (Sirius Red, A-D W 120;
E, F W 50).
These pictures show the actual comparative
condition of the livers with or without silymarin. Note the
dramatic difference in the ones protected by milk thistle.
The structure is much, much closer to normal in all these
examples.
Which of these would you want your
liver to look like?

DISCUSSION
The effects of silymarin on alcoholic liver disease are controversial,
with the presence4 or absence5 of positive effects. This issue
had not been resolved by prior animal studies, carried out
with rodents which did not duplicate the alcoholic liver fibrosis
produced in humans. This difficulty,
however, was overcome by the study of silymarin used, for
the first time, in a model of alcoholic liver cirrhosis in
the baboon.6 It allows for a full control of the 2 crucial variables, namely
alcohol and silymarin consumption. Under these conditions,
morphologic and biochemical parameters revealed a protective
effect of silymarin against alcohol-induced liver injury.
This statement attests to the overwhelmingly
positive results of the study with regard to the protective
action of silymarin.
The results were significant in terms of oxidative stress,
assessed by 4-hydroxynonenal, possibly the most reliable indicator
of oxidative liver injury. Positive results were also obtained
for ALT, lipids, and especially fibrosis and collagen metabolism.
Thus, these favorable effects in non-human
primates are consistent with some clinical trials,4 but not with others.5 Possible reasons for these discrepancies between the clinical
trials may include variability in alcohol consumption as well
as poor compliance with medication intake, not uncommon problems
in alcoholic populations. Thus, the negative outcome observed
in some of the clinical trials with silymarin may reflect
the actual intake of a low amount of silymarin, whereas some
of the positive trials may have been more successful in achieving
the desirable dosage.
This statement supports our recommendation
for the consistent use of Maximum Milk
Thistle at three capsule per day, every day.
Another difference between the human trials and the present
study is the fact that silymarin was used in the baboons to
prevent alcoholic fibrosis, whereas in humans, it was given
to treat patients with established alcoholic cirrhosis. Accordingly,
it might be useful, in future clinical trials, to achieve
and control the administration of sufficiently high doses
of silymarin, with emphasis on careful assessment of medication
compliance and of alcohol intake. In addition, it would be
indicated to include patients at an early stage of disease
in whom the effect of silymarin on the progression to cirrhosis
could be assessed, since the baboons
results reveal that silymarin slows the alcohol-induced disease
process and can prevent the cirrhosis.
Silymarin slows the disease process
for alcohol. And that process is not that different than the
disease process of viral hepatitis. In either case, inflammation
and fibrosis leads to cirrhosis, cirrhosis leads to death.
This makes me all the more adamant about the importance of
taking Maximum Milk Thistle (because
of its increased absorption) on a daily basis (because of
the need for adequate levels on a consistent basis).
Acknowledgments:
The authors thank L. Shoichet for skillful technical assistance,
A. Ponomarenko for graphic and statistical support, Dr. U.
Mengs (MADAUS AG) for his comments, and Y. Rodriguez for the
diligent secretarial assistance.
REFERENCES
1. Kuntz E, Kuntz HD. Hepatology:
Principles and Practice. Heidelberg, Germany: Springer-Verlag;
2002.
2. Mourelle M, Muriel P, Favari
L, et al. Prevention of CCl4-induced liver cirrhosis by silymarin.
Fundam Clin Pharmacol. 1989; 3:183-191.
PubMed
Abstract
3. Comoglio A, Tomasi A, Malandrino
S, et al. Scavenging effect of silipide, a new silybin-phospholipid
complex, on ethanol-derived free radicals. Biochem Pharmacol.
1995; 50:1313-1316.
PubMed
Abstract | CrossRef
4. Ferenci P, Dragosics B, Dittrich
H, et al. Randomized controlled trial of silymarin-treatment
in patients with cirrhosis of the liver. J Hepatology. 1989;
9:105-113.
PubMed
Abstract
5. Pares A, Planas R, Torres
M, et al. Effects of silymarin in alcoholic patients with
cirrhosis of the liver: results of a controlled, double-blind,
randomized and multicenter trial. J Hepatology. 1998; 28:615-621.
PubMed
Abstract | CrossRef
6. Lieber CS, DeCarli LM. Animal
models of chronic ethanol toxicity.In: Packer L, ed. Methods
in Enzymology: Oxygen Radicals in Biological Systems,
Part C; Orlando, Florida: Academic Press Inc.; 1994: 585-594.
7. Lieber CS, Leo MA, Mak KM,
et al. Choline fails to prevent liver fibrosis in ethanol-fed
baboons but causes toxicity. Hepatology. 1985; 5:561-572.
PubMed
Abstract
8. Van Waes L, Lieber CS. Early
perivenular sclerosis in alcoholic fatty liver: an index of
progressive liver injury. Gastroenterology. 1977; 73:646-650.
PubMed
Abstract
9. van Kuijk FJGM, Siakotos AN,
Fong LG, et al. Quantitative measurement of 4-hydroxyalkenals
in oxidized low-density lipoprotein by gas chromatography-mass
spectrometry. Anal Biochem. 1995; 224:420-424.
PubMed
Abstract
10. Homan R, Anderson MK. Rapid
separation and quantitation of combined neutral and polar
lipid classes by high-performance liquid chromatography and
evaporative light-scattering mass detection. J Chromatogr.
1998; 708:21-26.
PubMed
Abstract
11. Moshage H, Casini A, Lieber
CS. Acetaldehyde selectively stimulates collagen production
in cultured rat liver fat-storing cells but not in hepatocytes.
Hepatology. 1990; 12:511-518.
PubMed
Abstract
12. Maniatis T, Fritch EF, Sambrook
J. Gel electrophoresis.In: Maniatis T, Fritch EF, Sambrook
J, eds. Molecular Cloning: A Laboratory Manual,1st
ed. Cold Springs Harbor, NY, 1982: 161-75.
Journal of Clinical Gastroenterology 2003; 37(4):336-339
Copyright ) 2003 Lippincott Williams & Wilkins
All rights reserved
Click here to see what the
medical editors of the Journal of Clinical Gastroentorology
have to say about this study.
|